Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma That Has Relapsed After High-Dose Chemotherapy and Autologous Stem Cell Transplantation
Lymphoma
About this trial
This is an interventional treatment trial for Lymphoma focused on measuring recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, recurrent adult diffuse small cleaved cell lymphoma, recurrent adult diffuse mixed cell lymphoma, recurrent adult diffuse large cell lymphoma, recurrent adult immunoblastic large cell lymphoma, recurrent adult Burkitt lymphoma, recurrent mantle cell lymphoma, recurrent marginal zone lymphoma, recurrent small lymphocytic lymphoma, extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue, nodal marginal zone B-cell lymphoma, splenic marginal zone lymphoma
Eligibility Criteria
DISEASE CHARACTERISTICS: Diagnosis of relapsed B-cell non-Hodgkin's lymphoma (NHL) after high-dose chemotherapy and autologous stem cell transplantation Less than 25% bone marrow involvement with NHL as evidenced by unilateral or bilateral biopsy within the past 6 weeks Bone marrow biopsy should demonstrate 15-20% of cellular space occupied by normal hematopoiesis CD20 antigen expression in tumor tissue within the past year as evidenced by 1 of the following: Immunoperoxidase stains of tissue showing positive reactivity with L26 antibody Flow cytometry studies Measurable disease More than 2 cm bidimensionally No active CNS lymphoma No HIV- or AIDS-related lymphoma PATIENT CHARACTERISTICS: Age: 19 and over Performance status: WHO 0-2 Life expectancy: At least 3 months Hematopoietic: Absolute neutrophil count greater than 1,500/mm^3 Platelet count greater than 150,000/mm^3 No transfusion dependency Hepatic: Bilirubin less than 2.0 mg/dL SGOT or SGPT no greater than 2.5 times upper limit of normal (unless due to lymphomatous infiltration of the liver) Renal: Creatinine less than 2.0 mg/dL No active obstructive hydronephrosis Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for 6 months after study therapy HIV negative No active infection requiring oral or IV antibiotics No human antimurine antibody positivity No other major medical problems PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics At least 4 weeks since prior growth factors At least 4 weeks since prior biologic therapy No dependency on hematopoietic growth factors (e.g., epoetin alfa, interleukin-11, filgrastim [G-CSF], or sargramostim [GM-CSF]) No prior radioimmunotherapy No other concurrent biologic therapy of any kind Chemotherapy: See Disease Characteristics At least 4 weeks since any prior cytotoxic chemotherapy (6 weeks for nitrosoureas) No prior fludarabine No concurrent chemotherapy Endocrine therapy: No concurrent steroids except as maintenance for non-cancerous disease Radiotherapy: See Biologic therapy At least 4 weeks since prior radiotherapy No prior pelvic radiotherapy No prior radiotherapy to more than 25% of estimated bone marrow reserve No concurrent external beam radiotherapy Surgery: Not specified Other: Recovered from all prior therapy At least 4 weeks since prior immunosuppressants No other concurrent investigational drugs No other concurrent anti-cancer therapy
Sites / Locations
- UNMC Eppley Cancer Center at the University of Nebraska Medical Center